Adicet Bio, INC 8-K filings

Adicet Bio has been granted Fast Track Designation by the FDA for its ADI-270 therapy in patients with metastatic/advanced clear cell renal cell carcinoma.

Adicet Bio has received FDA clearance for its Investigational New Drug application for ADI-270, a novel CAR T-cell therapy, to treat relapsed/refractory renal cell carcinoma.

Adicet Bio's stockholders approved an increase in authorized shares, an amendment to the stock option plan, and officer liability protection at their annual meeting.

Adicet Bio has been granted Fast Track Designation by the FDA for its ADI-001 therapy in the treatment of relapsed/refractory class III or class IV lupus nephritis.

Adicet Bio announced its first quarter 2024 financial results, highlighted by a strong cash position and progress in clinical trials for its gamma delta T cell therapies.

Adicet Bio's ADI-270, an armored allogeneic anti-CD70 CAR T-cell therapy, shows strong preclinical results for multiple solid and hematological cancers.

Adicet Bio's ADI-270, an armored allogeneic CAR T-cell therapy, shows strong preclinical results, supporting an IND filing in Q2 2024.

Adicet Bio has established an at-the-market equity offering program with Jefferies LLC to sell shares of its common stock.

Adicet Bio announced its fourth quarter and full year 2023 financial results, highlighted by the expansion of its clinical pipeline into autoimmune diseases and an extended cash runway into the second half of 2026.

Adicet Bio has successfully priced a public offering of common stock and pre-funded warrants, expected to generate approximately $91.8 million in net proceeds.

Adicet Bio presented an updated corporate overview, emphasizing advancements in their allogeneic CAR T-cell therapies for autoimmune diseases and cancer, including upcoming clinical trial initiations and data updates.